SummitTX Capital’s Sanofi SNY Stock Holding History

SummitTX Capital’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,157	Closed	-$248K	–	1002
2026 Q1	$248K	Buy	+5,157	New	+$240K	0.01%	671
2025 Q2	–	Sell	-5,767	Closed	-$320K	–	992
2025 Q1	$320K	Buy	+5,767	New	+$312K	0.01%	645

Other funds holding SNY

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

SummitTX Capital's SNY Position: Q2 2026 in Review

SummitTX Capital sold out of Sanofi (SNY) in Q2 2026, closing a stake of 5,157 shares — an estimated $248K sold.

SummitTX Capital first reported a position in SNY in Q1 2025 and held it in 2 quarters. The position peaked at $320K in Q1 2025. 716 funds tracked by Wall St. Rank hold SNY as of Q2 2026.

SummitTX Capital reported no remaining Sanofi position as of Q2 2026 after selling out during the quarter.
SummitTX Capital sold 5,157 Sanofi shares in Q2 2026, an estimated $248K.
SummitTX Capital first reported a position in Sanofi in Q1 2025 and held it in 2 quarters.
SummitTX Capital's Sanofi position peaked at $320K in Q1 2025.
716 funds tracked by Wall St. Rank held Sanofi as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.